Zero Networks Raises $55M Series C to Usher in the “Era of the Defender”
3.6.2025 13:30:00 CEST | Business Wire | Press Release
Zero Networks, the cybersecurity company reclaiming microsegmentation to finally deliver on its promise, today announced it raised $55 million in Series C funding. The raise solidifies Zero Networks’ position at the forefront of the “Era of the Defender” – a paradigm shift in cybersecurity where the burden of effort no longer falls on defenders reacting to threats, but on attackers forced to confront proactive, identity- and network-driven controls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603407926/en/
Zero Networks is proud to have raised $55 million in Series C funding.
The round was led by Highland Europe, with participation from existing investors F2 Venture Capital, PICO Venture Partners, Venrock and U.S. Venture Partners (USVP). This brings Zero Networks’ total funding to more than $100 million. Jacob Bernstein, Principal at Highland Europe, will join the company’s board of directors.
Since its Series B, Zero Networks has tripled its customer base, doubled headcount, and experienced more than 300% revenue growth – driven by growing enterprise urgency around stopping lateral movement and enforcing true zero trust controls. Lateral movement remains a defining tactic in the majority of ransomware and supply chain attacks, yet the absence of microsegmentation leaves most organizations dangerously exposed. Traditional tools focus on the perimeter, but once breached, attackers can move freely, often undetected for days or weeks. That’s exactly what Zero Networks was built to stop.
At the heart of Zero Networks’ approach is its radically simple microsegmentation solution. While microsegmentation has long been hailed as the gold standard for stopping lateral movement, it has historically been viewed as too complex to implement and scale. Zero Networks has changed that narrative with an agentless, automated solution that finally makes microsegmentation both effective and effortless – an achievement validated by record-breaking growth in 2024 and consistent five-star customer reviews.
This new investment fuels the company’s next phase of growth, including team expansion across sales and marketing, research and development, and customer support. Additionally, funding will be used to increase go-to-market investments in North America, EMEA, and APAC and support continued innovation in Zero Networks’ award-winning solutions.
“Microsegmentation has long been the crown jewel of network defense; praised for its effectiveness but abandoned because of its complexity,” said Benny Lakunishok, CEO and Co-Founder of Zero Networks. “This funding raise validates everything we’ve claimed since day one: that we can make segmentation simple, scalable, and powerful enough to contain ransomware and stop lateral movement at its source. It also opens up a massive opportunity for every network defender out there to stop playing catch-up and start taking control.”
While Zero Networks leads with modern microsegmentation, its full suite of offerings also includes Zero Trust Network Access (ZTNA) and Identity Least Privilege solutions, available on a unified platform. By anchoring enforcement in identity, Zero Networks’ patented, MFA-driven approach ensures least privilege access across all users, devices, and workloads to deliver zero trust that actually lives up to its name.
“Cybersecurity’s most promising but often misunderstood tool is microsegmentation,” said Jacob Bernstein, Principal at Highland Europe. “This technique is essential to proactive zero trust architecture that prevents attacks by design rather than merely responding to them. Since the early days of evaluating Zero Networks, it was incredibly clear that their customers don’t just like Zero – they love it. This is a testament to everyone from the founding team to their most recent hires at all levels, hand-picked to serve Zero’s customers and build innovative solutions. I look forward to working closely with Zero Networks, a company that I believe is going to achieve phenomenal success and enormous outcomes for its customers.”
Zero Networks will be at Black Hat USA from Aug. 6–7, 2025. Visit the team at Booth 2251. Can’t wait until August? Experience the ease of Zero’s microsegmentation solution via a virtual self-guided product tour.
To learn more about Zero Networks, visit zeronetworks.com.
About Zero Networks
Zero Networks is revolutionizing network security with its effortless microsegmentation solution that stops ransomware and implements in days, not years. By automating asset tagging and policy creation, Zero Networks saves enterprises an average of 86% on total cost of ownership compared to legacy microsegmentation solutions that rely on time-intensive manual processes. Combined with advanced Identity Segmentation and Zero Trust Network Access solutions, and fortified by network-layer MFA, Zero Networks’ platform accelerates zero trust initiatives at companies of any size. This comprehensive approach enables organizations to stop lateral movement attacks, exceed compliance requirements, achieve top-tier audit scores, and pass every penetration test. For more information, visit zeronetworks.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603407926/en/
Contacts
Media Contact
Taylor Hadley
LaunchTech Communications
taylor@golaunchtech.com - sjacono@golaunchtech.com
978-877-2113
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom